Medtronic and Johnson & Johnson-backed Mitralign has so far secured $39.8m in series E funding but has not named the round's investors.
Mitralign, a US-based heart treatment developer backed by medical device maker Medtronic and healthcare company Johnson & Johnson, revealed $39.8m in series E funding today from undisclosed investors.
Founded in 2003, Mitralign is developing therapies for conditions affecting the heart valve, functional triscupid regurgitation (FTR) and functional mitral regurgitation (FMR), that can result in heart failure. FTR affects 1.6 million patients in the US, while FMR affects a combined eight million in the US and Europe.
The company will use…
